Infosys Claims Cognizant Poaching Employees of Helix Project

Infosys has submitted a fresh court filing in the US, accusing Cognizant of hiring away critical employees involved in the development of its healthcare platform, Helix. The complaint, dated June 13, 2025, specifically names 2 Cognizant leaders, Chief People Officer Kathryn Diaz and Americas President Surya Gummadi, for their alleged involvement in the hiring process, as per the Business Standard report.

Background of the Dispute

The issue ties back to earlier claims from January 2025, when Infosys accused Cognizant CEO Ravi Kumar S of delaying Helix’s rollout while he was still at Infosys. Kumar had led the Helix project before exiting Infosys in October 2022. He joined Cognizant as CEO in January 2023.

Key Hires Under Scrutiny

Infosys claims Cognizant later hired 2 senior executives from its Helix team. Shveta Arora, who worked closely on the platform, joined Cognizant in December 2023 as head of consulting. Another former Infosys executive, Ravi Kuchibhotla, came on board as chief strategy officer in August 2024.

Cognizant Responds and Reiterates Countersuit

Cognizant has denied the allegations, stating that Diaz was appointed after Kumar and dismissing the claims as misleading. The company also restated its own accusation that Infosys had previously misused trade secrets related to its healthcare IT product, TriZetto, a direct competitor to Helix.

The legal battle between the 2 IT firms began in 2024 and has since included charges related to intellectual property and talent movement. Infosys, in its latest filing, said the hiring activity was a deliberate attempt to interfere with Helix’s progress and demanded access to documents held by Diaz and Gummadi.

Read more: Global Diamond Industry Sees Renewed Spark in 2025: Rising Demand in India!

Infosys Share Price Performance

As of 09:25 AM on June 25, 2025, Infosys share price was trading at ₹1,592, a 0.66% increase, with a 17.19% decline over the past 6 months and a 2.44% increase over the past year.

Conclusion

Both companies are competing in the healthcare IT sector, with Helix and TriZetto targeting similar markets in North America. The case remains ongoing, with further legal steps expected in the coming months.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.